A Randomized, Controlled, Prospective and Multicenter Clinical Investigation Evaluating the Safety and Performance of ABIO3419 in Treating Knee Osteoarthritis
Latest Information Update: 07 Jul 2026
At a glance
- Drugs ABIO 3419 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Symatese
Most Recent Events
- 01 Jul 2026 Actual Primary Completion date changed to 1 Nov 2025.
- 01 Jul 2026 Status changed from recruiting to completed.
- 26 Feb 2025 Planned End Date changed from 1 Feb 2026 to 1 Mar 2026.